文献速递心脑血管急症消化、代谢与肾脏急症

急性心脏症状患者使用比索洛尔透皮制剂的尝试

An attempt at administering a transdermal formulation of bisoprolol in patients with acute cardiac symptoms.
PubMed 文献 · Am J Emerg Med · 2020-10-01
一句话结论回顾性研究提示比索洛尔透皮贴剂可能用于急性心肌缺血或心衰加重入院患者早期引入β阻滞剂,但需警惕低血压风险。

结果显示贴剂剂量与24小时内血压下降无显著相关,但与24小时内心率下降显著相关(p<0.05)。仅1例接受8 mg贴剂的患者出现一过性心动过缓(心率<50 bpm)。作者结论为该透皮制剂可能有助于急性心肌缺血或心衰相关心脏症状入院患者早期引入β阻滞剂,但因可能低血压风险需谨慎。

要点

  • 贴剂剂量与24小时内心率下降(ΔHR0-24 h)显著相关(p<0.05),提示心率反应与剂量相关。
  • 仅1例接受8 mg贴剂的患者出现一过性心动过缓(心率<50 bpm)。
  • 作者结论:透皮比索洛尔可能有助于此类患者早期引入β阻滞剂,但需警惕低血压风险。

适用人群与场景

  • 因心脏症状疑似急性冠脉综合征或心衰急性加重而入住京都桂医院心血管中心的患者,入院后接受比索洛尔透皮贴剂(Bisono® tape)者。

诊断标准与关键阈值

  • 原文未提及

处置流程与药物剂量

  • 原文未提及具体给药方案、剂量调整流程或目标值;仅描述使用比索洛尔透皮贴剂(Bisono® tape),并分析剂量与血压、心率变化的关系。

红旗征与不能漏的情况

  • 接受8 mg比索洛尔透皮贴剂的患者可能出现一过性心动过缓(心率<50 bpm),原文报告1例。
  • 作者提示因可能低血压风险需谨慎。

研究设计与关键结果

  • 主要结果:贴剂剂量与24小时内血压下降无显著相关;贴剂剂量与24小时内心率下降(ΔHR0-24 h)显著相关(p<0.05)。
  • 不良事件:仅1例接受8 mg贴剂的患者出现一过性心动过缓(心率<50 bpm)。

证据类型、等级与局限

  • 证据类型:回顾性病历调查(原文自述 retrospective survey of medical records)。
  • 原文未述局限性。

对床旁实践的改变

  • 对于因疑似急性冠脉综合征或心衰急性加重入院的心脏症状患者,比索洛尔透皮贴剂可能用于早期引入β阻滞剂,但需注意可能低血压风险。
  • 原文未提及适用与不适用人群的具体标准,也未提及常见陷阱。

指南或共识出处

  • 原文未提及

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

BACKGROUND: Bisono® is the world's first transdermal formulation of a bisoprolol, which is approved for the treatment of hypertension in Japan. We aimed to investigate the usefulness of this formulation in patients who were admitted to our hospital with cardiac symptoms suggestive of acute coronary syndrome or an acute exacerbation of heart failure.

METHODS: This study involved a retrospective survey of medical records from September 1, 2017 to April 30, 2018 obtained from the Cardiovascular Center of Kyoto Katsura Hospital. The clinical data of patients on admission who had received a transdermal formula of bisoprolol (Bisono® tape) were retrieved; their blood pressure and heart rate data were analyzed in relation to the doses of Bisono® tape administered.

RESULTS: Sixty-three patients received the Bisono® tape. Their final diagnoses included acute myocardial infarction, an exacerbation of heart failure, and atrial fibrillation. While there was no significant correlation observed between the administered doses of the drug and reduction in blood pressure achieved within 24 h after admission, there was a significant (p < 0.05) correlation between the doses of Bisono®tnd reduction in the heart rate within 24 h after admission (ΔHR0-24 h). Only one patient who received 8 mg of Bisono® exhibited temporal bradycardia (heart rate < 50 bpm).

CONCLUSION: The transdermal formulation of bisoprolol may be useful for the early introduction of β-blockers in patients admitted with cardiac symptoms associated with myocardial ischemia or heart failure. However, caution should be exercised because of the possible risk of hypotension.

来源:Am J Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Nozaki A, Kobayashi T, Naruhashi K, et al. An attempt at administering a transdermal formulation of bisoprolol in patients with acute cardiac symptoms. Am J Emerg Med. 2020. PMID: 33039223. doi:10.1016/j.ajem.2020.09.057

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。